Is cosentyx skin irritation common?

Is skin irritation common with Cosentyx?

Skin irritation ranks among the most frequent reactions reported by people taking Cosentyx. The prescribing information lists injection site reactions as a common side effect, with rates around 4% to 7% in clinical studies.

Why do companies challenge Cosentyx patents?

Cosentyx is protected by multiple patents covering its active ingredient secukinumab and its formulation. Companies seeking to launch biosimilars have challenged these patents in several jurisdictions, especially around the 2027 expiration of key U.S. patents. Companies often challenge patents to accelerate biosimilar entry and reduce market price.

How does Cosentyx compare with other biologics for skin conditions?

Cosentyx belongs to the interleukin-17 inhibitors class. It works differently from TNF inhibitors such as Humira or TNF-blockers such as Enbrel. Cosentyx clears skin faster than those agents in head-to-head trials for plaque psoriasis. It also shows high rates of skin clearance in patients who fail previous biologic treatments.

What side effects are patients asking about?

Patients frequently ask about injection site reactions, diarrhea, and nasopharyngitis. Injection site reactions appear as redness, swelling, or pain at the pen or syringe site. Many patients report that these irritation effects tend to lessen over time after repeated injections.

Can biosimilars enter before patent expiry?

Biosimilars to Cosentyx cannot legally enter the U.S. market before the 2027 patent cliff unless early patent challenges succeed. Current plans indicate biosimilar versions of secukinumab will arrive after the main compound patents expire.